AVIR Atea Pharmaceuticals
Atea Pharmaceuticals earnings company data as of 4:48 AM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 11 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by AVIR's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $25K bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Polly A. Murphy DirectorBuy$25K 6,100 shares at $4.17 +7.1% to stakeTraded May 18 Filed May 21
-
Polly A. Murphy DirectorBuy$25K 6,100 shares at $4.17 +7.1% to stakeTraded May 18, 2025 Filed May 20
Also filed in the last 12 months, not counted as buying or selling: 14 option exercises and 6 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 20 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.